J&J Seeks Approval For Doxil Plus Velcade In Multiple Myeloma

Supplemental claim for liposomal doxorubicin has a May 21 priority review date, J&J’s Ortho Biotech unit tells “The Pink Sheet” DAILY.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet